Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathy

Gómez-Almería, M.Martínez-González, L.Matos, A.T.Rodríguez-Cueto, C.Vaz, A.R.Martín-Baquero, R.Pérez de la Lastra, C.Infantes, R.Fernández-Ruiz, J.Palomo, ValleGil, C.Brites, D.Martínez, A.De Lago, E.2026-02-172026-02-172026https://hdl.handle.net/20.500.12614/4163application/pdfenAtribución-NoComercial-SinDerivadas 3.0 Españahttp://creativecommons.org/licenses/by-nc-nd/3.0/es/Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathyresearch article10.1016/j.neuropharm.2025.110804open access